Filing Scope and Business Context
Important identity discrepancy: The supplied filing is for Zeta Acquisition Corp. III, not Kura Oncology, Inc. It is a Form 10-K for the fiscal year ended December 31, 2011, filed March 30, 2012. The filing describes a Delaware development-stage, blank-check and shell company formed to pursue a business combination. It had identified no target, entered no definitive agreement, and conducted no operating business.
Financial Position and Results
- Revenue: None since inception on November 16, 2007. No revenue-producing operations were conducted.
- Net loss: $27,040 in 2011 versus $22,395 in 2010. The 2011 loss consisted primarily of general and administrative expenses of $23,440 and interest expense of $3,600.
- Loss per share: $0.01 basic and diluted in 2011 versus $0.00 in 2010, based on 5,000,000 weighted-average shares outstanding.
- Cash flow: Operating cash usage was $22,678 in 2011 versus $19,244 in 2010. There was no investing cash flow and no financing cash flow in 2011.
- Liquidity: Cash and cash equivalents were $4,220 at December 31, 2011, down from $26,898 at December 31, 2010. Total assets were $6,720 versus $29,398.
- Liabilities and debt: Total liabilities were $74,751 versus $70,389. This included $60,000 of unsecured, 6% notes payable to stockholders, $6,324 of accrued interest, $2,927 of accounts payable and $5,500 of accrued expenses.
- Equity: Stockholders’ deficit was $68,031 at year-end 2011 versus $40,991 at year-end 2010. Accumulated development-stage losses totaled $118,031.
- Margins: Not meaningful because the company had no revenue.
- Audit: The independent auditor reported that the financial statements fairly presented the company’s financial position and results in conformity with U.S. GAAP. The audit did not include an attestation report on internal control over financial reporting.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $4,645, or approximately 21%, from 2010.
- Operating cash usage increased by $3,434, or approximately 18%.
- Cash declined by $22,678, while total assets declined by $22,678.
- Total liabilities increased by $4,362, primarily because accrued interest rose from $2,724 to $6,324 and accounts payable increased from $2,165 to $2,927.
- No additional financing was received during 2011; 2010 included $35,000 of stockholder loan proceeds.
- The company remained a shell and had not identified or negotiated with any potential business-combination target.
Outlook, Risks and Unusual Items
- Management planned to continue searching for a business-combination target rather than pursue immediate earnings or operating revenue.
- Management stated that the company’s ability to continue as a going concern depended on obtaining financing, generating future profitable operations and completing a suitable reverse merger or other combination. No assurance of additional funding was provided.
- The company expected to rely on treasury funds, deferred service-provider fees and loans or investments from stockholders, management or other investors.
- After year-end, stockholders provided $25,000 of additional loans. Separately, the company issued $15,000 of 6% unsecured, demand notes on January 17, 2012 and a $10,000 note to Goldfield Partners on February 29, 2012.
- Key risks included limited cash, dependence on related-party funding, inability to identify or complete a transaction, dilution, lack of diversification, intense competition for acquisition targets and the possibility of acquiring an early-stage or financially unstable business.
- The company had no employees, paid no executive compensation, owned or rented no property, had no material legal proceedings and reported no material off-balance-sheet arrangements.
- Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2011; the filing states that this conclusion was not subject to auditor attestation.
Investor Verification Items
- Verify the issuer identity: the filing text names Zeta Acquisition Corp. III, while the request identifies Kura Oncology, Inc.
- Verify whether the requested period should be the fiscal year ended December 31, 2011 rather than “2011 Q4.”
- Confirm the company’s ability to fund operations beyond the reported $4,220 of year-end cash.
- Review the $60,000 of stockholder notes, accrued interest and the $25,000 of post-year-end related-party borrowings.
- Determine whether any business combination was subsequently identified or completed and whether substantial dilution occurred.
- Assess the going-concern uncertainty and the lack of operating revenue or an established business.